Yao Haiping, Ji Ming, Zhu Zhixiang, Zhou Jie, Cao Ran, Chen Xiaoguang, Xu Bailing
Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
Bioorg Med Chem. 2015 Feb 15;23(4):681-93. doi: 10.1016/j.bmc.2014.12.071. Epub 2015 Jan 8.
Poly(ADP-ribose)polymerase-1 (PARP-1) has emerged as a promising anticancer drug target due to its key role in the DNA repair process. In this work, a novel series of 1-benzyl-quinazoline-2,4(1H,3H)-dione derivatives were designed and synthesized as human PARP-1 inhibitors, structure-activity relationships were conducted and led to a number of potent PARP-1 inhibitors having IC50 values of single or double digit nanomolar level. Compound 7j was a potent PARP-1 and PARP-2 inhibitor and it could selectively kill the breast cancer cells MX-1 and MDA-MB-468 with mutated BRCA1/2 and PTEN, respectively, in comparison with homologous recombination proficient cell types such as breast cancer cells MDA-MB-231. In addition, compound 7j displayed the strongest potentiation effect on temozolomide in MX-1 cells (PF50=3.77) in this series of PARP-1 inhibitors.
聚(ADP - 核糖)聚合酶 -1(PARP -1)因其在DNA修复过程中的关键作用,已成为一个有前景的抗癌药物靶点。在本研究中,设计并合成了一系列新型的1 - 苄基 - 喹唑啉 -2,4(1H,3H) - 二酮衍生物作为人PARP -1抑制剂,进行了构效关系研究,得到了一些IC50值处于个位数或两位数纳摩尔水平的强效PARP -1抑制剂。化合物7j是一种强效的PARP -1和PARP -2抑制剂,与同源重组功能正常的细胞类型(如乳腺癌细胞MDA - MB -231)相比,它能分别选择性杀死具有BRCA1/2和PTEN突变的乳腺癌细胞MX -1和MDA - MB -468。此外,在这一系列PARP -1抑制剂中,化合物7j在MX -1细胞中对替莫唑胺表现出最强的增效作用(PF50 = 3.77)。